Comparative effectiveness of two versions of a caring contacts intervention in healthcare providers, staff, and patients for reducing loneliness and mental distress: A randomized c... von Radin, Anna K., Shaw, Jenny, Brown, Siobhan P., Torres, Jessica, Harper, Maggie, Flint, Hilary, Fouts, Tara, McCue, Elizabeth, Skeie, Anton, Peña, Cecelia, Youell, Jonathan, Doty-Jones, Amelia, Wilson, Jacob, Flinn, Lee, Austin, George, Chan, Kwun C.G., Zheng, Zihan, Fruhbauerova, Martina, Walton, Michael, Kerbrat, Amanda, Comtois, Katherine Anne

Volltext

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens von Niesvizky, Ruben, Flinn, Ian W, Rifkin, Robert, Gabrail, Nashat, Charu, Veena, Clowney, Billy, Essell, James, Gaffar, Yousuf, Warr, Thomas, Neuwirth, Rachel, Zhu, Yanyan, Elliott, Jennifer, Esseltine, Dixie-Lee, Niculescu, Liviu, Reeves, James

Volltext

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma von Locke, Frederick L, Miklos, David B, Jacobson, Caron A, Perales, Miguel-Angel, Kersten, Marie-José, Oluwole, Olalekan O, Ghobadi, Armin, Rapoport, Aaron P, McGuirk, Joseph, Pagel, John M, Muñoz, Javier, Farooq, Umar, van Meerten, Tom, Reagan, Patrick M, Sureda, Anna, Flinn, Ian W, Vandenberghe, Peter, Song, Kevin W, Dickinson, Michael, Minnema, Monique C, Riedell, Peter A, Leslie, Lori A, Chaganti, Sridhar, Yang, Yin, Filosto, Simone, Shah, Jina, Schupp, Marco, To, Christina, Cheng, Paul, Gordon, Leo I, Westin, Jason R

Volltext

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma von Leonard, John P, Kolibaba, Kathryn S, Reeves, James A, Tulpule, Anil, Flinn, Ian W, Kolevska, Tatjana, Robles, Robert, Flowers, Christopher R, Collins, Robert, DiBella, Nicholas J, Papish, Steven W, Venugopal, Parameswaran, Horodner, Andrew, Tabatabai, Amir, Hajdenberg, Julio, Park, Jaehong, Neuwirth, Rachel, Mulligan, George, Suryanarayan, Kaveri, Esseltine, Dixie-Lee, de Vos, Sven

Volltext

Optimising the yield from bronchoalveolar lavage on human participants in infectious disease immunology research von Shaw, Jane Alexandra, Meiring, Maynard, Allies, Devon, Cruywagen, Lauren, Fisher, Tarryn-Lee, Kasavan, Kesheera, Roos, Kelly, Botha, Stefan Marc, MacDonald, Candice, Hiemstra, Andriёtte M., Simon, Donald, van Rensburg, Ilana, Flinn, Marika, Shabangu, Ayanda, Kuivaniemi, Helena, Tromp, Gerard, Malherbe, Stephanus T., Walzl, Gerhard, du Plessis, Nelita

Volltext

Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial in Progress) von Flinn, Ian W., Friedman, Judah, Ho, Linda, Lee, Hun Ju

Volltext

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial von Horwitz, Steven, O'Connor, Owen A, Advani, Ranjana, Rossi, Giuseppe, Kim, Won Seog, Illés, Árpád, Tobinai, Kensei, Yeh, Su-Peng, Shustov, Andrei, Yuen, Sam, Iyer, Swaminathan, Hua, Zhaowei, Little, Meredith, Rao, Shangbang, Woolery, Joseph, Manley, Thomas, Aboulafia, David, Bartlett, Nancy, Belada, David, Yehuda, Dina Ben, Benedetti, Fabio, Bordessoule, Dominique, Chang, Hung, Cheong, June Weon, Choi, Ilseung, Colita, Andrei, Congui, Angela Giovanna, Dang, Nam, Davison, Kelly, de Guibert, Sophie, Delwail, Vincent, di Raimondo, Francesco, Do, Young Rok, Domingo, Eva, Douvas, Michael, Dreyling, Martin, Fay, Keith, Ferrero, Silvia Fernandez, Flinn, Ian Winchester, Forero-Torres, Andres, Friedberg, Jonathan, Fukuhara, Noriko, Garcia-Marco, Jose, Cruz, Jorge Gayoso, Gurion, Ronit, Christensen, Jacob Haaber, Hajek, Roman, Hatake, Kiyohiko, Horowitz, Netanel, Illes, Arpad, Illidge, Tim, Ishizawa, Kenichi, Islas-Ohlmayer, Miguel, Jacobsen, Eric, Janakiram, Murali, Jurczak, Wojciech, Kaminski, Mark, Kato, Koji, Kim, Won Seog, Iyer, Swaminathan, Kuo, Ching-Yuan, Lazaroiu, Mihaela Cornelia, Lee, Jong-Seok, Lennard, Anne, LaRosee, Paul, Levi, Itai, Link, Brian, Maisonneuve, Herve, Maruyama, Dai, Mayer, Jiri, Mocikova, Heidi, Morra, Enrica, Morschhauser, Franck, Munoz, Javier, Nagai, Hirokazu, Opat, Stephen, Pettengell, Ruth, Pezzutto, Antonio, Pfreundschuh, Michael, Pro, Barbara, Reyes, Ruben, Izquierdo, Antonia Rodriguez, Rossi, Giuseppe, Ruan, Jia, Salles, Gilles, Sarriera, Jose, Shibayama, Hirohiko, Shustov, Andrei, Suh, Cheolwon, Sureda, Anna, Tanimoto, Mitsune, Taniwaki, Masafumi, Tilly, Herve, Tsukamoto, Norifumi, Wilhelm, Martin, Yamamoto, Kazuhito, Yeh, Su-Peng, Yun, Hwan Jung, Zain, Jasmine, Zinzani, Pier Luigi

Volltext

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study von Keating, Michael J., Flinn, Ian, Jain, Vinay, Binet, Jacques-Louis, Hillmen, Peter, Byrd, John, Albitar, Maher, Brettman, Lee, Santabarbara, Pedro, Wacker, Bret, Rai, Kanti R.

Volltext

Brentuximab vedotin in combination with nivolumab, doxorubicin, and dacarbazine in newly diagnosed patients with advanced-stage Hodgkin lymphoma (Trial in Progress) von Friedman, Judah D., Lee, Hun Ju, Ho, Linda, Flinn, Ian

Volltext

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma von Friedman, Judah, Lee, Hun Ju, Ho, Linda, Flinn, Ian W.

Volltext

BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB, DOXORUBICIN, AND DACARBAZINE IN NEWLY DIAGNOSED PATIENTS WITH ADVANCED HODGKIN LYMPHOMA (SGN35‐027, TRIAL IN PROGRESS) von Flinn, I., Friedman, J. D., Ho, L., Lee, H. J.

Volltext

Genome-wide gene expression responses to experimental manipulation of Saccharomyces cerevisiae repressor activator protein 1 (Rap1) expression level von Kalra, S., Peyser, R., Ho, J., Babbin, C., Bohan, N., Cortes, A., Erley, J., Fatima, M., Flinn, J., Horwitz, E., Hsu, R., Lee, W., Lu, V., Narch, A., Navas, D., Kalu, I., Ouanemalay, E., Ross, S., Sowole, F., Specht, E., Woo, J., Yu, K., Coolon, J.D.

Volltext

Maternal microchimerism in healthy adults in lymphocytes, monocyte/macrophages and NK cells von Loubière, Laurence S, Lambert, Nathalie C, Flinn, Laura J, Erickson, Timothy D, Yan, Zhen, Guthrie, Katherine A, Vickers, Kathy T, Nelson, J Lee

Volltext

Ibrutinib (Ibr) dose modification for management of early cardiac adverse events in patients with chronic lymphocytic leukemia: Pooled analysis of 7 clinical trials von Tedeschi, A., Ahn, I. E., Fraser, G. A. M., Greil, R., Munir, T., Kay, N. E., Flinn, I. W., Lee, S., Saifan, C., Kearbey, J., Patel, S., Barrientos, J. C.

Volltext

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine for Advanced Stage Classical Hodgkin Lymphoma: Efficacy and Safety Results from the Single Arm Phase 2 Study von Lee, Hun Ju, Flinn, Ian W., Melear, Jason, Ramchandren, Rod, Friedman, Judah, Burke, John M., Linhares, Yuliya, Gonzales, Paul Alan, Raval, Mihir, Chintapatla, Rangaswamy, Feldman, Tatyana, Yimer, Habte A., Islas-Ohlmayer, Miguel, Dean, Asad, Rana, Vishal, Gandhi, Mitul, Renshaw, John Scott, Ho, Linda, Fanale, Michelle A., Guo, Wenchuan, Yasenchak, Chris

Volltext

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Updated Efficacy and Safety Results from the Single-Arm Phase 2 St... von Lee, Hun, Flinn, Ian W., Melear, Jason, Ramchandren, Rod, Friedman, Judah, Burke, John M., Linhares, Yuliya, Gonzales, Paul Alan, Raval, Mihir, Chintapatla, Rangaswamy, Feldman, Tatyana, Yimer, Habte, Islas-Ohlmayer, Miguel, Dean, Asad, Rana, Vishal, Gandhi, Mitul, Renshaw, John, Ho, Linda, Fanale, Michelle A., Guo, Wenchuan, Yasenchak, Christopher A.

Volltext

Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and C... von Shadman, Mazyar, Mato, Anthony R., Batlevi, Connie Lee, Flinn, Ian W., Gutierrez, Martin, Uemura, Marc, Stevens, Don A., Morillo, Daniel, Byrd, John C., Frigault, Melanie M., Clemens, George, Huang, Xin, Izumi, Raquel, Wong, Harvey, Breed, Renee, Garban, Hermes, Johnson, Amy J., Stelte-Ludwig, Beatrix, Mithal, Arushi, Birkett, Joseph, Hamdy, Ahmed, Rogers, Kerry A.

Volltext

Phase II study of single‐agent bortezomib for the treatment of patients with fludarabine‐refractory B‐cell chronic lymphocytic leukemia von Faderl, Stefan, Rai, Kanti, Gribben, John, Byrd, John C., Flinn, Ian W., O'Brien, Susan, Sheng, Shihong, Esseltine, Dixie‐Lee, Keating, Michael J.

Volltext

Analysis of peripheral neuropathy (PN) using clinician- and patient-reported outcomes (ClinRO and PRO) in the POLARIX study von Trneny, Marek, Fogliatto, Laura, Gardner, Faithlore Patrice, Flinn, Ian W., Larouche, Jean-Francois, Haioun, Corinne, Canales Albendea, Miguel Angel, Goto, Hideki, Hajek, Roman, Salles, Gilles A., Qiu, Jiaheng, Campinha-Bacote, Avrita, Yan, Mark, Kothari, Rucha, Man, Gabriel, Sahin, Deniz, Hirata, Jamie, Lee, Calvin, Tilly, Herve, Flowers, Christopher

Volltext

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Advanced Stage Classic Hodgkin Lymphoma: Preliminary Safety Results from the Single-Arm Phase 2 Study (SGN3... von Lee, Hun Ju, Flinn, Ian W., Melear, Jason, Ramchandren, Rod, Friedman, Judah, Burke, John M., Linhares, Yuliya, Peterson, Matthew R., Raval, Mihir, Chintapatla, Rangaswamy, Feldman, Tatyana A., Yimer, Habte, Islas-Ohlmayer, Miguel, Dean, Asad, Rana, Vishal, Gandhi, Mitul D., Renshaw, John, Gillespie-Twardy, Amanda L., Ho, Linda, Fanale, Michelle A., Guo, Wenchuan, Yasenchak, Christopher A.

Volltext